TDF Use Across the Age Spectrum: From Fetus to Adolescent - Anna Turkova, MD

International Workshop on HIV & Pediatrics 2015

Debate: CD4 Assays Are No Longer Needed for Care of Children in Lowresource Countries - Ted Ruel, MD

International Workshop on HIV & Pediatrics 2015

CON ‐ standpoint - Diana Gibb, MD, MRCP, MSc

International Workshop on HIV & Pediatrics 2015

Pediatric Treatment Cascade: What Do We Need to Reach “90‐90‐90” for Children - Elaine Abrams, MD

International Workshop on HIV & Pediatrics 2015

Virologic Outcomes of Children Switched from Lopinavir/Ritonavir‐ to Efavirenz‐Based Antiretroviral Treatment: a retrospective cohort study - Kirsten Reichmuth

International Workshop on HIV & Pediatrics 2015

Lopinavir ritonavir (1:1 ratio) in the presence of rifampicin is not inferior to lopinavir ritonavir (4:1 ratio) in the absence of rifampicin in HIV children. Interim analysis of an open label sequential non- randomized phar- Mark Cotton

International Workshop on HIV & Pediatrics 2015

The effect of systemic exposure to efavirenz, sex and age on the risk of virological non‐suppression in HIV‐infected African children - Andrzej Bienczak

International Workshop on HIV & Pediatrics 2015

Durability of first‐line antiretroviral therapy (ART) in children in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) - Ruth Goodall

International Workshop on HIV & Pediatrics 2015

Reasons for delayed ART initiation in children with HIV in South Africa - Chloe Teasdale

International Workshop on HIV & Pediatrics 2015

Efavirenz‐based therapy may simplify antiretroviral LPV‐based therapy initiated in HIV‐1‐infected children before the age of 2 in West‐Africa: the MONOD trial ANRS 12206 - Valeriane Leroy

International Workshop on HIV & Pediatrics 2015

Bridging Worlds: Perinatally‐Infected Youth and Transition to Adult Care - Caroline Foster, MBBS, MRCPCH

International Workshop on HIV & Pediatrics 2015

Anxiety and depression in young people with perinatal HIV and their HIV negative siblings - Marthe Le Prevost

International Workshop on HIV & Pediatrics 2015

Innovative Adherence Interventions for HIV‐Infected Youth - Rachel Vreeman, MD, MS

International Workshop on HIV & Pediatrics 2015

Hepatitis B Treatment Response to TDF in 3TC‐experienced Perinatally HIVinfected Adolescents - Linda Aurpibul

International Workshop on HIV & Pediatrics 2015

Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease and Liver Fibrosis among Perinatally HIV‐infected Asian Adolescents - Tavitiya Sudjaritruk

International Workshop on HIV & Pediatrics 2015

Week 48 safety and efficacy of a rilpivirine (TMC278)‐based regimen in HIVinfected treatment‐naïve adolescents: PAINT Phase II trial - Patricia Flynn

International Workshop on HIV & Pediatrics 2015

Second‐line ART treatment and resistance outcomes of Asian children - Annette Sohn, MD

International Workshop on HIV & Pediatrics 2015

Overview lecture on Pros and Cons - Lynne Mofenson, MD

International Workshop on HIV & Pediatrics 2015

PRO ‐ standpoint - Jennifer Jao, MD, MPH

International Workshop on HIV & Pediatrics 2015

Debate: HIV‐Exposed Uninfected Infants Require Lifelong Follow Up in All - Thanyawee Puthanakit, MD

International Workshop on HIV & Pediatrics 2015

HIV exposed uninfected South African infants experience greater severity but not frequency of common infectious diseases than HIV unexposed uninfected infants - Amy Slogrove

International Workshop on HIV & Pediatrics 2015

Effectiveness of conditional cash transfers to increase retention in care and adherence to PMTCT services: A randomized controlled trial - Marcel Yotebieng

International Workshop on HIV & Pediatrics 2015

Psychosocial factors in younger versus older HIV‐infected pregnant women initiating antiretroviral therapy in Cape Town, South Africa - Marcia Wong

International Workshop on HIV & Pediatrics 2015

In utero Tenofovir Exposure is Not Associated with Poor Fetal Long Bone Growth - Jennifer Jao

International Workshop on HIV & Pediatrics 2015